Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
Launched by THE LYMPHOMA ACADEMIC RESEARCH ORGANISATION · Jan 6, 2020
Trial Information
Current as of June 28, 2025
Recruiting
Keywords
ClinConnect Summary
The Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry is a clinical trial aimed at understanding a rare type of cancer called anaplastic large cell lymphoma that can occur in women with breast implants. This condition is not common, which is why the French and Belgian health authorities have created this registry to collect information about cases of BIA-ALCL. By gathering data, researchers hope to learn more about the disease and improve care for those affected.
To be eligible for this trial, participants must be adult women diagnosed with BIA-ALCL and have breast implants. There are no specific exclusions mentioned, making it open to a wide range of patients. Women who join the registry can expect to share their health information, which will help doctors and researchers better understand this condition. The trial is currently recruiting participants in France and Belgium, and it represents an important step towards improving knowledge and treatment of this rare cancer associated with breast implants.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Adult patients with an anaplastic large cell lymphoma associated with breast implants
- Exclusion Criteria:
- • -
About The Lymphoma Academic Research Organisation
The Lymphoma Academic Research Organisation (LARO) is a leading clinical trial sponsor dedicated to advancing the understanding and treatment of lymphoma through innovative research and collaboration. Comprising a network of esteemed academic institutions and healthcare professionals, LARO focuses on designing and conducting rigorous clinical trials that evaluate novel therapies and therapeutic strategies. By fostering partnerships with industry stakeholders and leveraging cutting-edge methodologies, LARO aims to improve patient outcomes and contribute to the evolving landscape of lymphoma treatment. Its commitment to excellence in research is underscored by a patient-centered approach, ensuring that the needs and experiences of those affected by lymphoma remain at the forefront of its initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edegem, , Belgium
Paris, , France
Bordeaux, , France
Rouen, , France
Lyon, , France
Marseille, , France
Brussels, , Belgium
Gent, , Belgium
Nantes, , France
Leuven, , Belgium
Brussel, , Belgium
Saint Cloud, , France
Pierre Bénite, , France
Dijon, , France
Brussels, , Belgium
Creteil, , France
Perpignan, , France
Pau, , France
Brest, , France
Strasbourg, , France
Colmar, , France
Bruges, , Belgium
Bruxelles, , Belgium
Yvoir, , Belgium
Saint Malo, , France
Liège, , Belgium
Avignon, , France
Lille, , France
Montpellier, , France
Reims, , France
Toulouse, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials